MAUNA KEA TECHNOLOGIES (FR:ALMKT)
:ALMKT
Top Page
MAUNA KEA TECHNOLOGIES
(ALMKT)
Select Model
Select Model
Rating:46Neutral
Price Target:
€0.12
▲(48.75% Upside)
Action:UpgradedDate:01/29/26
The score is primarily constrained by poor financial performance (sharp revenue decline, large losses, and negative equity). Technicals provide partial support from an uptrend and positive MACD, but overbought momentum signals increase near-term risk. Valuation remains unattractive/unclear due to negative earnings and no dividend support.
Positive Factors
Recurring Consumables Revenue
The company earns recurring revenue from disposables and leasing, which creates a predictable, repeatable revenue stream tied to procedure volume. Over months this supports unit economics and aftermarket margins, aiding cash generation if installed base and procedure rates stabilize.
Negative Factors
Significant Revenue Decline
A 30.6% year-over-year revenue drop materially weakens scale and the installed-base economics that underpin consumable sales. Prolonged top-line contraction can erode pricing leverage, limit margin recovery, and impede investment in commercialization over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Recurring Consumables Revenue
The company earns recurring revenue from disposables and leasing, which creates a predictable, repeatable revenue stream tied to procedure volume. Over months this supports unit economics and aftermarket margins, aiding cash generation if installed base and procedure rates stabilize.
Read all positive factors
MAUNA KEA TECHNOLOGIES (ALMKT) vs. iShares MSCI France ETF (EWQ)
Market Cap
€34.58M
Dividend YieldN/A
Average Volume (3M)830.17K
Price to Earnings (P/E)―
Beta (1Y)1.06
Revenue Growth-0.80%
EPS Growth24.14%
CountryFR
Employees65
SectorGeneral
Sector StrengthN/A
IndustryMedical - Devices
Share Statistics
EPS (TTM)N/A
Shares Outstanding192,097,270
10 Day Avg. Volume1,028,958
30 Day Avg. Volume830,169
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-0.44
Price to Sales (P/S)1.41
P/FCF Ratio-1.65
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.03
Revenue Forecast (FY)€8.25M
MAUNA KEA TECHNOLOGIES Business Overview & Revenue Model
Company Description
Mauna Kea Technologies SA, a medical device company, manufactures and sells medical devices in Europe and internationally. It offers range of medical devices in gastroenterology, pulmonology, and urology areas. Its product portfolio includes Cellv...
How the Company Makes Money
MAUNA KEA TECHNOLOGIES generates revenue through the sale of its proprietary imaging systems, including the Cellvizio platform, as well as disposable accessories required for its operation. The company earns money from direct sales to healthcare i...
MAUNA KEA TECHNOLOGIES Financial Statement Overview
Summary
Income Statement
35
Negative
Balance Sheet
25
Negative
Cash Flow
40
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 8.18M | 7.66M | 11.03M | 7.48M | 7.70M | 6.53M |
| Gross Profit | 7.07M | 6.44M | 8.93M | 3.91M | 5.71M | 3.63M |
| EBITDA | -4.45M | -7.97M | -1.46M | -9.93M | -11.23M | -11.43M |
| Net Income | -10.39M | -10.40M | -3.73M | -11.18M | -13.45M | -12.79M |
Balance Sheet | ||||||
| Total Assets | 12.66M | 16.25M | 22.94M | 19.79M | 24.75M | 20.61M |
| Cash, Cash Equivalents and Short-Term Investments | 663.00K | 1.92M | 7.91M | 3.15M | 11.89M | 8.66M |
| Total Debt | 32.87M | 31.93M | 29.77M | 29.20M | 28.70M | 26.96M |
| Total Liabilities | 42.08M | 40.63M | 40.21M | 39.72M | 35.08M | 32.69M |
| Stockholders Equity | -29.42M | -24.39M | -17.28M | -19.92M | -10.33M | -12.08M |
Cash Flow | ||||||
| Free Cash Flow | -5.00M | -6.54M | -1.14M | -8.97M | -11.37M | -9.07M |
| Operating Cash Flow | -4.80M | -6.32M | -753.00K | -8.83M | -10.27M | -7.99M |
| Investing Cash Flow | 10.00K | -149.00K | -354.00K | -57.00K | -1.14M | -999.00K |
| Financing Cash Flow | 1.68M | 483.00K | 5.96M | 109.00K | 14.65M | 7.68M |
MAUNA KEA TECHNOLOGIES Technical Analysis
Neutral
0.08
Price Trends
0.16
Positive
0.12
Positive
0.11
Positive
Market Momentum
<0.01
Positive
50.18
Neutral
42.03
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALMKT, the sentiment is Neutral. The current price of 0.08 is below the 20-day moving average (MA) of 0.19, below the 50-day MA of 0.16, and below the 200-day MA of 0.11, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 50.18 is Neutral, neither overbought nor oversold. The STOCH value of 42.03 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for FR:ALMKT.
MAUNA KEA TECHNOLOGIES Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
50 Neutral | €22.42M | -5.20 | -17.18% | ― | 138.92% | 11.14% | |
47 Neutral | €165.74M | -0.80 | 59.08% | ― | 6.75% | 15.48% | |
46 Neutral | €34.58M | -0.39 | ― | ― | -0.80% | 24.14% | |
46 Neutral | €28.28M | -1.41 | 467.60% | ― | -4.70% | -64.31% | |
44 Neutral | €27.15M | -2.19 | -14.58% | ― | 5.10% | 17.34% | |
42 Neutral | €233.13M | 26.96 | 1.32% | ― | 12.47% | -65.87% |
* General Sector Average
FR:ALMKT
MAUNA KEA TECHNOLOGIES
0.18
0.07
66.67%
FR:ALTHE
Theraclion SA
0.47
0.33
228.47%
FR:ALNOV
Novacyt
0.37
-0.10
-20.76%
FR:ALERS
Eurobio-Scientific SA
23.30
-0.70
-2.92%
FR:ALIKO
Ikonisys SA
1.42
0.01
1.07%
FR:ALMDT
Median Technologies
4.41
1.71
63.51%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.